Natera (NASDAQ:NTRA) Price Target Raised to $240.00

Natera (NASDAQ:NTRA) had its price objective lifted by JPMorgan Chase & Co. from $210.00 to $240.00 in a research note released on Friday morning,Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the medical research company’s stock.

Several other equities research analysts also recently issued reports on the company. Evercore ISI boosted their price objective on Natera from $190.00 to $250.00 and gave the company an “outperform” rating in a report on Friday. Wells Fargo & Company raised their target price on Natera from $175.00 to $190.00 and gave the company an “equal weight” rating in a report on Friday. BNP Paribas upgraded shares of Natera to a “hold” rating and set a $172.00 price target on the stock in a research note on Monday, October 27th. BTIG Research increased their price target on shares of Natera from $210.00 to $230.00 and gave the stock a “buy” rating in a research report on Friday. Finally, Cowen reissued a “buy” rating on shares of Natera in a research note on Friday, August 8th. Seventeen equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $206.74.

Natera Stock Performance

Shares of NTRA stock opened at $199.57 on Friday. The firm has a market cap of $27.39 billion, a P/E ratio of -87.15 and a beta of 1.74. The firm’s 50 day moving average price is $177.75 and its 200-day moving average price is $163.91. Natera has a one year low of $125.38 and a one year high of $203.23.

Natera (NASDAQ:NTRA) last posted its earnings results on Thursday, November 6th. The medical research company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.25). The company had revenue of $592.18 million during the quarter, compared to analyst estimates of $514.55 million. Natera had a negative net margin of 14.61% and a negative return on equity of 25.20%. The firm’s revenue for the quarter was up 34.7% on a year-over-year basis. During the same quarter last year, the business posted ($0.26) EPS. Natera has set its FY 2025 guidance at EPS. As a group, research analysts predict that Natera will post -1.49 EPS for the current fiscal year.

Insider Activity

In other Natera news, insider Solomon Moshkevich sold 3,000 shares of the stock in a transaction that occurred on Wednesday, October 1st. The shares were sold at an average price of $159.99, for a total value of $479,970.00. Following the sale, the insider directly owned 117,559 shares of the company’s stock, valued at approximately $18,808,264.41. This represents a 2.49% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CFO Michael Burkes Brophy sold 2,491 shares of the firm’s stock in a transaction on Tuesday, September 30th. The shares were sold at an average price of $162.05, for a total transaction of $403,666.55. Following the completion of the sale, the chief financial officer owned 69,189 shares in the company, valued at $11,212,077.45. The trade was a 3.48% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 224,889 shares of company stock worth $43,232,062. Insiders own 5.63% of the company’s stock.

Institutional Trading of Natera

Institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. raised its position in shares of Natera by 2.3% during the 2nd quarter. Vanguard Group Inc. now owns 12,676,653 shares of the medical research company’s stock worth $2,141,594,000 after acquiring an additional 282,826 shares in the last quarter. JPMorgan Chase & Co. increased its stake in Natera by 9.4% in the third quarter. JPMorgan Chase & Co. now owns 11,628,914 shares of the medical research company’s stock valued at $1,871,914,000 after purchasing an additional 1,003,129 shares during the last quarter. Price T Rowe Associates Inc. MD raised its holdings in Natera by 56.3% during the first quarter. Price T Rowe Associates Inc. MD now owns 10,537,743 shares of the medical research company’s stock worth $1,490,144,000 after purchasing an additional 3,795,315 shares in the last quarter. Geode Capital Management LLC raised its holdings in Natera by 7.0% during the second quarter. Geode Capital Management LLC now owns 2,552,725 shares of the medical research company’s stock worth $430,640,000 after purchasing an additional 166,768 shares in the last quarter. Finally, Invesco Ltd. lifted its position in shares of Natera by 13.7% during the 1st quarter. Invesco Ltd. now owns 2,035,979 shares of the medical research company’s stock worth $287,908,000 after buying an additional 245,719 shares during the last quarter. 99.90% of the stock is owned by hedge funds and other institutional investors.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.